Maternal Stress on Human Milk and Infant Outcomes

Postpartum Depression Clinical Trial

Official title:

Effects of Maternal Stress on Human Milk Composition and Subsequent Infant Outcomes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04821544
• Other study ID #: 20-024
• Secondary ID: 5U54GM104944-08
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2021
• Est. completion date: June 30, 2025

Study information

• Verified date: September 2023
• Source: University of Idaho
• Contact: Yimin Chen, PhD
• Phone: 2088857264
• Email: yiminc[@]uidaho.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overarching purpose of this study is to determine if a modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) will reduce stress and increase self-compassion in mothers of preterm infants and beneficially modify the human milk produced, and subsequently improve infant health.

Description:

During every two-week period, newly admitted preterm infants (<36 weeks gestational age) will be recruited at performance site OHSU NICU and block-randomized to either control (standard of care) or intervention (modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) group. The purpose of the nested cohorts is to minimize the postpartum time difference among cohort mothers. Each nested MBSC cohort will undergo the 8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator. Maternal data: The Perceived Stress Scale (PSS) and Self-Compassion Scale-Short Form (SCS-SF) will be given to mothers from both groups pre- and post-intervention, and during the 4th week. Saliva, urine, stool, and human milk samples will be collected at the same time points as above. Additional maternal data include: age, race, height, weight (pre-pregnancy and last weight before delivery), parity, delivery mode, chorioamnionitis, preeclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome, antenatal antibiotics, anti-depressants or other mood-altering/neurochemical medications (current and during pregnancy), diagnosis of depression or other mental illness within the previous 5 years, history of postpartum depression and postpartum psychosis, diabetes, hypertension, heart disease, and any inflammatory or autoimmune diseases. Infant data: Gestational age, birth weight, ventilation requirement, surgical interventions, patent ductus arteriosus, growth, nutrition prescriptions, saliva, urine and stool samples. Data collection: All data (not including biosamples) will be collected using REDCap hosted within the UI system. Sample measurements: Maternal salivary cortisol (marker of stress) and oxytocin (marker of anxiety and "social-closeness") concentrations will be measured using ELISA. Human milk proteins will be identified using mass spectrometry-based proteomics. Following proteomic analyses, targeted proteins will be quantified using ELISA and Western Blot. Both maternal and infant saliva, urine and stool samples will be used for metabolomic and transcriptomic sequencing to identify metabolic and molecular changes, respectively, in both mothers and infants. Infant systemic oxidative stress will be measured through urine F2-isoprostanes concentrations (ELISA), and infant intestinal inflammation will be determined with stool calprotectin concentrations (ELISA).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Mothers of preterm infants (<36 weeks gestation) at Oregon Health and Sciences University Exclusion Criteria: -

Related Conditions & MeSH terms

• Depression, Postpartum
• Obstetric Labor, Premature
• Postpartum Depression
• Preterm Labor

Intervention

Behavioral:
• Mindfulness-based intervention (with a focus on self-compassion; MBSC)
8-week MBSC intervention with a focus on increasing self-compassion

Locations

Country	Name	City	State
United States	Kootenai Health	Coeur d'Alene	Idaho
United States	Oregon Health & Science University	Portland	Oregon

Sponsors (5)

Lead Sponsor	Collaborator
University of Idaho	Kootenai Health, National Institute of General Medical Sciences (NIGMS), Oregon Health and Science University, Oregon State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maternal Stress - Biomarker Change	Salivary cortisol - Change from Baseline cortisol to 4 and 8 weeks	Baseline to 4 and 8 weeks
Primary	Maternal Stress - Psychometric Measure Change	Perceived Stress Scale (PSS) - Change from Baseline PSS to 4 and 8 weeks; The Perceived Stress Scale (PSS) is validated and the most widely used instrument to measure perception of stress. The PSS includes 14 questions inquiring about feelings and thoughts during the past month expressed through frequency. The PSS will be used pre-intervention, post-intervention (8 weeks), and at the mid-point of the intervention (4 weeks). The scale for each question ranges from 0-4. The PSS measures how often the responder found life to be unpredictable, uncontrollable, and overloaded. Higher score indicates higher perceived stress. The total score ranges between 0-56.	Baseline to 4 and 8 weeks
Primary	Maternal Self-compassion - Biomarker Change	Salivary oxytocin - Change from Baseline oxytocin to 4 and 8 weeks	Baseline to 4 and 8 weeks
Primary	Maternal Self-compassion - Psychometric Measure Change	Self-Compassion Scale-Short Form (SCS-SF) - Change from Baseline SCS-SF to 4 and 8 weeks; The Self-Compassion Scale-Short Form (SCS-SF)19 is a shortened and highly correlated (r = 0.97) scale (12 items) from the original 26-item SCS. The SCS-SF measures six key components of self-compassion using a scale that ranges from 1-5: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Self-compassion is associated with psychological well-being and is therefore often measured alongside stress and anxiety. High score indicates higher self-compassion. The total score ranges between 0-60.	Baseline to 4 and 8 weeks
Secondary	Human Milk Proteins & Peptides Change	Protein and peptide profiles will be measured using proteomic & peptidomic analyses to assess human milk protein and peptide changes from baseline to 4 and 8 weeks as a function of maternal changes in stress/self-compassion. These are measured outcomes.	Baseline to 4 and 8 weeks
Secondary	Maternal Metabolomic & Transcriptomic Changes	Maternal metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to changes in stress/self-compassion. These are measured outcomes.	Baseline to 4 and 8 weeks
Secondary	Infant Metabolomic & Transcriptomic Changes	Infant metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to maternal changes in stress/self-compassion, and human milk protein/peptide profile changes. These are measured outcomes.	Baseline to 4 and 8 weeks